^
    3ms
    OGT and QIAGEN announce partnership that unlocks a complete sample to report workflow for SureSeq NGS panels (Oxford Gene Technology Press Release)
    "The partnership between OGT...and QIAGEN Digital Insights (QDI)...expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq NGS panels. Purpose-built for variant interpretation and clinical reporting, QCI Interpret delivers AI-powered, expert-curated classifications along with oncologist-reviewed summaries and transparent evidence links. Through this collaboration, SureSeq NGS panel users gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result."
    Licensing / partnership
    6ms
    QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership (Qiagen)
    "QIAGEN...today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics."
    Licensing / partnership
    |
    QIAcuity Digital PCR IVD Assay
    6ms
    QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) (Businesswire)
    "QIAGEN N.V...and Incyte...announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies."
    Licensing / partnership
    6ms
    QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships (Qiagen)
    "The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN’s reach in MRD testing and cover solid tumors and hematological cancers."
    Licensing / partnership
    |
    Foresight CLARITY™
    7ms
    QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions (Qiagen)
    "QIAGEN...today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications."
    Clinical data
    7ms
    QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software (Qiagen)
    "QIAGEN...today announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests."
    Licensing / partnership
    8ms
    QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 (Qiagen)
    "QIAGEN N.V... today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling...These new developments will be showcased at the American Association for Cancer Research (AACR) Annual Meeting 2025, from April 25-30 in Chicago."
    Clinical data
    8ms
    QIAGEN’s QCI Interpret One selected by Royal Marsden NHS Foundation Trust to expand Marsden360 liquid biopsy service for ESR1 testing for breast cancer patients (Qiagen)
    "QIAGEN Digital Insights... today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) Interpret One, is supporting The Royal Marsden National Health Service (NHS) Foundation Trust’s new offering for ESR1 genomic testing, a mutation associated with breast cancer, as part of its workflow for Marsden360, an innovative liquid biopsy service."
    Licensing / partnership
    1year
    QIAGEN’s QIAcuityDx digital PCR system is now included in the Australian Register of Therapeutic Goods (Qiagen)
    "QIAGEN today announced the inclusion of the QIAcuityDx digital PCR System in the Australian Register of Therapeutic Goods (ARTG). This pivotal addition to QIAGEN’s portfolio is now expanding digital PCR into clinical diagnostics, enabling labs to harness its precision and efficiency for applications in oncology and infectious diseases. The instrument and accessories are IVDR-certified."
    Clinical
    1year
    QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications (Qiagen)
    "QIAGEN...announced key updates to its sample technologies solutions for non-invasive liquid biopsy applications for use in research and clinical applications such as oncology, prenatal care and organ transplantation."
    Clinical data
    1year
    QIAGEN Digital Insights expands Biopharma collaboration with Neo4j to advance biomedical data analysis (Qiagen)
    "QIAGEN Digital Insights...today announced the expansion of its strategic partnership with Neo4j®, the world's leading graph database and analytics company. The collaboration will enable Neo4j Graph Database and Graph Data Science capabilities to integrate more deeply with the QIAGEN Biomedical Knowledge Base (BKB) product line, unlocking hidden patterns and relationships in biomedical data, and revealing powerful new insights to advance drug discovery, drug repurposing and translational research."
    Licensing / partnership
    1year
    QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology (Qiagen)
    "QIAGEN...announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics."
    Launch